Back to Search Start Over

Cytomegalovirus infection and cardiovascular outcomes in abdominal organ transplant recipients: A systematic review and meta-analysis.

Authors :
Arvanitis P
Davis MR
Farmakiotis D
Source :
Transplantation reviews (Orlando, Fla.) [Transplant Rev (Orlando)] 2024 Dec; Vol. 38 (4), pp. 100860. Date of Electronic Publication: 2024 May 25.
Publication Year :
2024

Abstract

Introduction: Despite advancements in Cytomegalovirus (CMV) management, its impact on graft function, mortality, and cardiovascular (CV) health of organ transplant recipients (OTR) remains a significant concern. We investigated the association between CMV infection and CV events (CVE) in organ (other than heart) transplant recipients.<br />Methods: We conducted a comprehensive literature search in PubMed and EMBASE, including studies that reported on CMV infection or disease and post-transplantation CVE. Studies of heart transplant recipients were excluded.<br />Results: We screened 3875 abstracts and 12 clinical studies were included in the final analysis, mainly in kidney and liver transplant recipients. A significant association was observed between CMV infection and an increased risk of CVE, with a pooled unadjusted hazard ratio (HR) of 1.99 (95% Confidence Intervals [CI] 1.45-2.73) for CMV infection and 1.59 (95% CI 1.21-2.10) for CMV disease. Pooled adjusted HR were 2.17 (95% CI 1.47-3.20) and 1.77 (95% CI 0.83-3.76), respectively. Heterogeneity was low (I <superscript>2</superscript>  = 0%) for CMV infection, suggesting consistent association across studies, and moderate-to-high for CMVdisease (I <superscript>2</superscript>  = 50% for unadjusted, 53% for adjusted HR).<br />Discussion: We found a significant association between CMV infection and CV risk in abdominal OTR, underscoring the importance of proactive CMV surveillance and early treatment. Future research should aim for more standardized methodologies to fully elucidate the relationship between CMV and CV outcomes, potentially informing novel preventive and therapeutic strategies that could benefit the CV health of OTR.<br />Competing Interests: Declaration of competing interest DF has received research support from Viracor, Astellas, Merck, and Astra-Zeneca, and consultant fee from Viracor. All other authors have nothing to disclose.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1557-9816
Volume :
38
Issue :
4
Database :
MEDLINE
Journal :
Transplantation reviews (Orlando, Fla.)
Publication Type :
Academic Journal
Accession number :
38815340
Full Text :
https://doi.org/10.1016/j.trre.2024.100860